{"title": "Pfizer steers group B strep vax towards late-stage immunogenicity study over complex efficacy trial", "author": "Max Bayer", "url": "https://www.fiercebiotech.com/biotech/pfizer-hopes-regulators-greenlight-ph3-immunogenicity-study-group-b-strep-vax", "hostname": "fiercebiotech.com", "description": "Given the challenges of running an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer's top vaccine executive hopes that regulators will allow an immunogenicity study for approval ins | Given the challenges of running an efficacy study for a group B streptococcus (GBS) vaccine, Pfizer's top vaccine executive hopes that regulators will allow an immunogenicity study for approval instead, just as they have for the New York pharma's meningitis B and pneumococcal vaccines.", "sitename": "FierceBiotech", "date": "2023-08-24", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}